Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
LG Life Science LTD. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'LG Life Science LTD. - Product Pipeline Review - 2016', provides an overview of the LG Life Science LTD.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by LG Life Science LTD., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of LG Life Science LTD. - The report provides overview of LG Life Science LTD. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses LG Life Science LTD.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features LG Life Science LTD.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate LG Life Science LTD.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for LG Life Science LTD. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding LG Life Science LTD.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 6 LG Life Science LTD. Snapshot 7 LG Life Science LTD. Overview 7 Key Facts 7 LG Life Science LTD. - Research and Development Overview 8 Key Therapeutic Areas 8 LG Life Science LTD. - Pipeline Review 12 Pipeline Products by Stage of Development 12 Pipeline Products - Monotherapy 13 Pipeline Products - Combination Treatment Modalities 14 Pipeline Products - Partnered Products 15 Partnered Products/Combination Treatment Modalities 16 Pipeline Products - Out-Licensed Products 17 Out-Licensed Products/Combination Treatment Modalities 18 LG Life Science LTD. - Pipeline Products Glance 19 LG Life Science LTD. - Late Stage Pipeline Products 19 Pre-Registration Products/Combination Treatment Modalities 19 Phase III Products/Combination Treatment Modalities 20 LG Life Science LTD. - Clinical Stage Pipeline Products 21 Phase II Products/Combination Treatment Modalities 21 Phase I Products/Combination Treatment Modalities 22 LG Life Science LTD. - Early Stage Pipeline Products 23 Preclinical Products/Combination Treatment Modalities 23 Discovery Products/Combination Treatment Modalities 24 LG Life Science LTD. - Unknown Stage Pipeline Products 25 Unknown Products/Combination Treatment Modalities 25 LG Life Science LTD. - Drug Profiles 26 (gemigliptin + glimepiride) - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 (gemigliptin + metformin hydrochloride) - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 (gemigliptin + rosuvastatin calcium) - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 (lercanidipine hydrochloride + valsartan) - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 adalimumab biosimilar - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 etanercept biosimilar - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Eupenta - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 exenatide SR - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 infliximab biosimilar - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 interferon alfa-2a SR - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 LBDE - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 LBVC - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 LBVD - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 LBVE-013 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 LBVE-014 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 LC-231306 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 LC-280126 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 LC-280391 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 LC-34AD3 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 LC-350189 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 LC-541239 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 LC-65AOD3 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 LD-02GIFRO - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Monoclonal Antibody to Inhibit VEGF for Cancer - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 NecX - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 nivocasan - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 rituximab biosimilar - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Small Molecule to Inhibit PAR-1 for Atherothrombosis - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Small Molecules for Obesity - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Small Molecules to Inhibit 20S Proteasome for Multiple Myeloma and Solid Tumor - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 somatropin - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 somatropin SR - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 LG Life Science LTD. - Pipeline Analysis 59 LG Life Science LTD. - Pipeline Products by Target 59 LG Life Science LTD. - Pipeline Products by Route of Administration 62 LG Life Science LTD. - Pipeline Products by Molecule Type 63 LG Life Science LTD. - Pipeline Products by Mechanism of Action 64 LG Life Science LTD. - Dormant Projects 67 LG Life Science LTD. - Locations And Subsidiaries 68 Head Office 68 Other Locations & Subsidiaries 68 Appendix 70 Methodology 70 Coverage 70 Secondary Research 70 Primary Research 70 Expert Panel Validation 70 Contact Us 70 Disclaimer 71
List of Tables LG Life Science LTD., Key Facts 7 LG Life Science LTD. - Pipeline by Indication, 2016 10 LG Life Science LTD. - Pipeline by Stage of Development, 2016 12 LG Life Science LTD. - Monotherapy Products in Pipeline, 2016 13 LG Life Science LTD. - Combination Treatment Modalities in Pipeline, 2016 14 LG Life Science LTD. - Partnered Products in Pipeline, 2016 15 LG Life Science LTD. - Partnered Products/ Combination Treatment Modalities, 2016 16 LG Life Science LTD. - Out-Licensed Products in Pipeline, 2016 17 LG Life Science LTD. - Out-Licensed Products/ Combination Treatment Modalities, 2016 18 LG Life Science LTD. - Pre-Registration, 2016 19 LG Life Science LTD. - Phase III, 2016 20 LG Life Science LTD. - Phase II, 2016 21 LG Life Science LTD. - Phase I, 2016 22 LG Life Science LTD. - Preclinical, 2016 23 LG Life Science LTD. - Discovery, 2016 24 LG Life Science LTD. - Unknown, 2016 25 LG Life Science LTD. - Pipeline by Target, 2016 60 LG Life Science LTD. - Pipeline by Route of Administration, 2016 62 LG Life Science LTD. - Pipeline by Molecule Type, 2016 63 LG Life Science LTD. - Pipeline Products by Mechanism of Action, 2016 65 LG Life Science LTD. - Dormant Developmental Projects,2016 67 LG Life Science LTD., Other Locations 68 LG Life Science LTD., Subsidiaries 69
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
